<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Subclinical <z:mp ids='MP_0001845'>inflammation</z:mp> leads to <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and <z:hpo ids='HP_0006279'>beta-cell dysfunction</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>This study aimed to assess whether levels of circulating transforming growth factor-beta1 (TGF-beta1)-a central, mainly immunosuppressive, and anti-inflammatory cytokine-were associated with incident type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: We measured serum levels of TGF-beta1 from 460 individuals with and 1,474 individuals without incident type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in a prospective case-cohort study within the population-based MONICA (MONItoring of Trends and Determinants in CArdiovascular Disease)/KORA (Cooperative Health Research in the Region of Augsburg) cohort </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Elevated TGF-beta1 concentrations were associated with higher, not lower, risk for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (age-, sex-, and survey-adjusted hazard ratios [95% CI] for increasing TGF-beta1 tertiles: 1.0, 1.08 [0.83-1.42], and 1.41 [1.08-1.83]; P(for) (trend) = 0.012) </plain></SENT>
<SENT sid="4" pm="."><plain>Adjustment for BMI and metabolic and lifestyle factors had virtually no impact on the effect size </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSIONS: Elevated serum concentrations of the cytokine TGF-beta1 indicate an increased risk for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>TGF-beta1 may be upregulated to counterbalance metabolic and immunological disturbances preceding type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>